MetaVia's DA-1726 Shows Promising Results in Obesity Treatment Clinical Trials

MetaVia's Promising Breakthrough in Obesity Treatment: DA-1726 Clinical Trial Results

MetaVia Inc. announces encouraging results from its Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin analog designed for obesity treatment. The trial focuses on patients with cardiometabolic diseases, a critical area of concern as obesity continues to rise globally. In the non-titrated 48 mg cohort, patients experience significant weight loss and metabolic improvements by Day 54. Specifically, participants show an average weight loss of 9.1% or 21.2 lbs, alongside a statistically significant reduction in waist circumference of 9.8 cm (3.8 inches), with a p-value of 0.022. These results indicate that DA-1726 could represent a significant advance in obesity therapies, potentially outpacing existing treatments in effectiveness.

The trial also reveals notable improvements in metabolic health, with patients demonstrating a 12.3 mg/dL reduction in fasted glucose levels from a baseline of 105.3 mg/dL. Furthermore, the reduction in liver stiffness by 23.7% suggests a direct hepatic effect, underscoring the comprehensive benefits of DA-1726 beyond mere weight loss. Hyung Heon Kim, president and CEO of MetaVia, points to the glucagon component in DA-1726 as a key factor in promoting visceral fat loss, which may contribute to its superior efficacy compared to traditional GLP-1 agonists. Such insights position DA-1726 as a promising candidate for not only addressing obesity but also improving associated metabolic disorders.

Despite some mild to moderate gastrointestinal events reported by participants, the trial does not see any treatment-related discontinuations, further supporting the tolerability of DA-1726. By Day 26, patients already achieve a 6.1% weight loss (14.6 lbs) and a waist circumference reduction of 5.8 cm (2.3 inches), indicating early signs of effectiveness. The extended eight-week trial period thus provides a solid foundation for continued development of DA-1726 as a potential best-in-class therapy in the fight against obesity and related health challenges.

In related news, MetaVia's ongoing commitment to research and development in cardiometabolic diseases illustrates the company's strategic focus on innovative solutions. The results from the DA-1726 trial are expected to drive further clinical investigations and could pave the way for future partnerships in the biotechnology sector. As the company progresses, stakeholders remain keenly interested in how these developments may reshape treatment paradigms in obesity management.